INNOVATE (VATE) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue rose 33% year-over-year to $364.8 million, driven by strong Infrastructure segment performance, while Life Sciences and Spectrum saw declines.

• Net loss attributable to shareholders narrowed to between $16.8 million and $17.2 million, improving from $24.5–$25.8 million in Q1 2025.

• Adjusted EBITDA increased to $19.7 million from $7.2 million, reflecting higher gross profit and improved operational performance.

• Substantial doubt exists about the company's ability to continue as a going concern due to upcoming debt maturities and covenant risks.

• Infrastructure segment delivered strong sales and backlog, Life Sciences achieved regulatory milestones, and Spectrum advanced strategic projects despite advertising softness.

Financial highlights

• Infrastructure revenue grew 35.1% year-over-year to $357.9 million; Life Sciences revenue fell 48.4% to $1.6 million; Spectrum revenue declined to $5.3 million.

• Gross profit increased to $53.5 million from $45.5 million year-over-year.

• Adjusted EBITDA for Infrastructure was $23.0 million, Life Sciences $(2.0) million, Spectrum $0.7 million.

• Cash and cash equivalents stood at $134.6 million as of March 31, 2026, up from $112.1 million at year-end 2025.

• Total principal outstanding indebtedness was $699 million, primarily due to PIK interest accruals.

Outlook and guidance

• Infrastructure backlog remains robust at $1.8 billion, supporting visibility into 2026 and 2027, with strong sales activity and a healthy pipeline.

• Management is pursuing asset sales, debt refinancing, and capital raises to address liquidity and covenant risks.

• Life Sciences expects further regulatory and commercial progress, with MediBeacon targeting additional approvals and ongoing clinical studies.

• Spectrum anticipates improved performance as regulatory tailwinds and strategic investments take effect, despite near-term advertising softness.

• No formal financial guidance provided; compliance with debt milestones and asset sales are critical for ongoing operations.